AY-1001

AY-1001 is a preclinical **small-molecule organic lithium coordination compound** being developed as a next-generation mood stabilizer for **bipolar disorder**, particularly for antimanic and maintenance applications. Publicly available preclinical literature describes AY-1001 as a novel lithium-containing compound with molecular formula **C9H16LiNO4** that was designed to improve on conventional **lithium carbonate** by achieving **faster onset, shorter half-life, higher blood-brain barrier penetration, and lower systemic toxicity** in animal studies. Its therapeutic concept appears to be delivery of lithium to the central nervous system with improved pharmacokinetic and toxicokinetic properties relative to inorganic lithium salts, rather than modulation of a newly disclosed molecular target. The exact sponsoring company is not clearly identified in the provided source, but the asset is supported by a peer-reviewed 2025 publication and associated patenting claims.

Other names

IsoLiPro